Focused Ultrasound Microbubble Aggregation for Brain Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering diagnostic or therapeutic agents to specific brain regions are hindered by the inability to selectively manipulate discrete brain areas, with systemic treatments causing side effects due to non-specific receptor binding, and existing localized delivery methods either require opening the blood-brain barrier (BBB) or are inefficient.
Innovation Solution
A method using ultrasound-controllable drug carriers, specifically microbubbles loaded with diagnostic or therapeutic agents, which are aggregated and then released using focused ultrasound (FUS) to achieve localized delivery without compromising the BBB, employing aggregation and uncaging FUS sequences to concentrate and release the agents with high precision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic administration of small molecules is used to treat CNS disorders, then the drugs can reach the brain, but they cause significant side effects by acting in non-targeted brain regions and organs
Solution Approach 1:
The patent applies local quality by using focused ultrasound to create a highly localized region of drug release at the target brain site. The microbubbles are concentrated and activated only in the specific brain region of interest, ensuring that the therapeutic agent is delivered locally rather than systemically. This resolves the contradiction by maintaining effective drug concentration at the target while preventing off-target side effects.
Solution Approach 2:
The patent uses microbubbles as an intermediary carrier system. These microbubbles serve as temporary vehicles that transport the therapeutic agent through the bloodstream to the target site, where they are activated by focused ultrasound. This intermediary approach allows controlled local release without requiring systemic distribution, thereby preventing off-target binding while ensuring adequate drug delivery to the brain.
2Quantity of substance
If FUS-mediated BBB opening is used for drug delivery, then localized delivery to the brain is achieved, but repeated BBB opening may cause severe consequences including immune response and infection risk
Solution Approach 1:
The patent applies partial action by using focused ultrasound parameters that are sufficient to activate microbubbles and release drugs locally but below the threshold required to open the blood-brain barrier. The microbubbles are activated through acoustic radiation force and cavitation at controlled energy levels, achieving localized drug release without causing BBB disruption. This resolves the contradiction by providing the minimum necessary action for drug delivery while avoiding excessive action that would damage the BBB.
3Measurement precision
If transcranial magnetic stimulation or penetrating electrodes are used to target specific brain circuits, then localized neural manipulation is achieved, but the methods are highly invasive or have low spatial resolution
Solution Approach 1:
The patent replaces mechanical/invasive methods (penetrating electrodes) with a non-invasive acoustic system. Focused ultrasound waves are used to activate microbubbles at the target brain site without requiring physical penetration of the skull or brain tissue. This substitution achieves high spatial resolution through acoustic focusing while eliminating the invasiveness of electrode-based methods, resolving the contradiction between precision and ease of operation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for highly efficient, localized delivery of small molecule drugs to specific brain regions without opening the BBB, maintaining BBB integrity and avoiding tissue damage, enabling millimeter-precision modulation of brain circuits.
Implementation Method 1
aggregating the drug carriers inside the blood vessel by exposing the drug carriers to radiation forces, the radiation forces being generated by applying an aggregation FUS sequence to the drug carriers in a target region
Implementation Method 2
releasing the diagnostic or therapeutic agent from the drug carriers by application of an uncaging FUS sequence to a target region
Data Source
AI summary
In a method for enhancing localized delivery of a diagnostic or therapeutic agent using focused ultrasound (FUS), ultrasound-controllable drug carriers are administered into a blood vessel. Each drug carrier comprises an ultrasound-sensitive microbubble loaded with the diagnostic or therapeutic agent. The drug carriers are aggregated inside the vessel both along a radial direction and a longitudinal direction by application of an aggregation FUS sequence. Subsequently the diagnostic or therapeutic agent is released from the drug carriers by application of an uncaging FUS sequence. The aggregation and uncaging sequences are applied using FUS below a threshold power level such that harmful cavitation is avoided, as evidenced by the absence of broadband emissions and preferably non-integer harmonics from an emission spectrum of the drug carriers. Thereby damage to the vasculature by the FUS sequence is avoided. The method can in particular be employed to deliver drugs to the brain without opening the blood-brain barrier.